Abstract
The current state of relapse prevention in schizophrenia is very unsatisfactory. Under routine treatment conditions 50% of our schizophrenic patients suffer a relapse within one year of their most recent episode (Gaebel and Pietzcker 1985). Patients with first episode schizophrenia must be readmitted to inpatient treatment an average of two times during the 5 year period following their first episode and spend an average of 300 days in the hospital during this time (Maurer and Biehl 1988). Approximately 70% of all hospitalized schizophrenic patients are readmissions (Kissling et al. 1990).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bäuml J, Wais A, Meurer T, Kissling W (1988) Compliance improvement with a long-term treatment of schizophrenic patients through a specific educational program for relatives. Psychopharmacology 96:223
Benkert O, Hippius H (1986) Psychiatrische Pharmakotherapie. Springer, Berlin Heidelberg New York Tokyo
Gaebel W, Pietzcker A (1983) Indikation zur neuroleptischen Langzeitmedikation — Standardverfahren oder individualprognostisch geleitete Intervention? Nervenarzt 54:467–476
Gaebel W, Pietzcker A (1985) One-year outcome of schizophrenic patients — the interaction of chronicity and neuroleptic treatment. Pharmacopsychiatry 18:235–239
Helmchen H (1979) Neuroleptische Langzeitmedikation in der Praxis. Mkurse Ärztl Fortbild 29:800–801
Kane JM (1985) Compliance issues in outpatient treatment. J Clin Psychopharmacol 5:22–27
Kissling W (1988) Consensus regarding indication for prophylactic neuroleptic treatment -necessary, but unattainable? In: Barnes TRE (ed) Depot neuroleptics: a consensus. Mediscript, London
Kissling W, Möller HJ, Bäuml J, Dietzfelbinger T, Winter I (1990) Fluanxol Depot 10% versus Haloperidol-Decanoat. Dosierung und Applikationsintervalle. In: Müller-Oerlinghausen B, Möller HJ, Rüther E (eds) Thioxanthene in der neuroleptischen Behandlung. Springer, Berlin Heidelberg New York
Lewandowski L, Buchkremer G (1988) Therapeutische Gruppenarbeit mit Angehörigen schizophrener Patienten. Z Klin Psychol 17:210–224
Lungershausen E (1981) Probleme der neuroleptischen Langzeitbehandlung bei schizophrenen Erkrankungen. pmi-pharm, Frankfurt
Maurer K, Biehl H (1988) Klinikaufenthalte und produktive Rückfälle bei ersterkrankten Schizophrenen. Determinanten des Zeitverlaufs zwischen stationären Aufnahmen bzw. schizophrenen Rezidiven über fünf Jahre. Nervenheilkunde 7:279–290
Müller P (1983) Was sollen wir Schizophrenen raten: medikamentöse Langzeitprophylaxe oder Intervallbehandlung? Nervenarzt 54:477–485
Nedopil N, Rüther E, Hippius H (1982) Neue Aspekte der Neuroleptika-Therapie. Schwerpunkt-med 5(2):25–29
Schüssler G (1985) Medikamentöse Behandlung von schizophrenen Patienten in der nervenärztlichen Praxis. In: Linden M, Lipski C, Pietzcker A (eds) Der schizophrene Patient in der Nervenarztpraxis. Thieme, Stuttgart
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Kissling, W. (1991). Federal Republic of Germany: Neuroleptic Relapse Prevention. In: Kissling, W. (eds) Guidelines for Neuroleptic Relapse Prevention in Schizophrenia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-86922-8_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-86922-8_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-53985-8
Online ISBN: 978-3-642-86922-8
eBook Packages: Springer Book Archive